Psychedelic
Startup
Consulting

The psychedelic industry is moving fast. Regulatory windows are opening, investor interest is growing, and the clinical evidence base is maturing. Psilonautica works with founders at the earliest stages to navigate the emerging field confidently

Stages We Work With
Pre-Seed
Seed
Series A
Growth

10+

Years of psychedelic industry experience

12

Clients advised across 12 countries

10+

Experienced contractors across the globe

5

Working languages across the team
the challenge

The landscape is promising but complex

Starting a psychedelic business means operating at the intersection of clinical science, shifting regulation, cautious capital markets, and evolving public perception. The structural challenges are consistent no matter the regulations.
1
Regulatory frameworks are still being written
What’s permitted today may not be tomorrow, and what’s prohibited today may not be next year. Founders who build on a regulatory assumption rather than a regulatory analysis are exposed.
2
Investor due diligence is unusually rigorous
Funds in the psychedelic space have specific expectations around compliance, clinical rationale, and exit pathways that require preparation well beyond standard pitch materials.
3
The reputational stakes are higher than most
A single misstep can close doors that are difficult to reopen. Getting the framing right from the start is not optional.
4
Strategic guidance is structurally required
This is not an industry where a founder can figure it out as they go. The cost of early missteps compounds. Getting the right advice early is the most efficient investment a startup can make.
Our Work

Strategic consulting for psychedelic founders

Psilonautica provides early-stage psychedelic startups with the expertise guiding larger, better-resourced organisations. We work with founders at the earliest stages through to growth, wherever strategic input is most needed.
Business Model Validation
Validating your operating model against current and anticipated regulatory conditions in your target markets before you build infrastructure.
Identifying the most viable route to legal operation, clinical authorisation, or product approval for your specific model.
Preparing the evidence base, compliance documentation, and strategic narrative that specialist psychedelic investors expect, structured around what funds in this sector actually look for.
Helping founders identify the credentialled advisors and clinical partners that strengthen both operations and investor confidence, and knowing which roles matter at which stage.
Crafting the language that accurately represents your work to regulators, press, and the public. What you say shapes how seriously you are taken.
Our advisors have direct experience across the UK, US, Canada, Australia, and beyond, with active relationships in the regulatory bodies, clinical networks, and investor communities that matter.
how we work

Our Approach

Clear, structured engagement from first contact to outcome is the way we work with all clients.

1
You book an introductory call to assess your needs
We understand your operating model, target markets, and immediate regulatory questions before committing to scope.
2
We send you a plan of how we’d address those needs
A written scope, timeline, and fee structure agreed before any work begins. No surprises.
3
We gather experts and explore your goals
The right advisors for your specific jurisdiction, service type, and stage, tailored for your goals.
4
We achieve measurable results
Clear outputs: regulatory assessments, investor materials, model reviews, or communications frameworks, all delivered on schedule.
The Team

Advisors with startup experience

Our startup advisory work draws on direct operational, investment, and regulatory experience across the psychedelic industry.
James Bunn headshot
James Bunn
Founder · Operations & Strategy
Background in law with hands-on operational experience across the psychedelic and cannabis space. Has supported startups from initial structuring through to operational scale across multiple international markets.
Lucas McHugh headshot
Lucas McHugh
Business Strategy · Investment
25 years working with early-stage companies and investments. Skills combine investment strategy, fundraising, and business development. Has helped build, develop, and scale many companies across diverse sectors.
Eddie Jacobs Headshot
Dr. Eddie Jacobs
Ethicist · Regulatory Support
Postdoctoral fellow at Johns Hopkins; PhD from Oxford. Provides ethics consultation, protocol review, and regulatory support to organisations across the psychedelic value chain, including early-stage companies.
common questions

What to expect

Questions clients typically raise before engaging us. Ask us anything else directly.
Do you work with pre-revenue startups?
Yes. Some of the most valuable consulting work happens before a business has launched. We work with founders at the idea stage through to Series A and beyond, depending on where strategic input is most needed.
Our advisors have active expertise across the UK, US, Canada, Australia, and New Zealand. For clients operating in other jurisdictions, we assess coverage on a case-by-case basis and will be upfront about where the limits of our expertise lie.
We advise on investor readiness and can help prepare materials, but do not act as a placement agent or broker. We can facilitate introductions where appropriate within our network.
An introductory call to understand your operating model and immediate questions, followed by a written scope, timeline, and fee structure. Initial consultations can typically be arranged within a week of first contact.

Let's help you ahieve your goals

Building something serious in the psychedelic space requires more than a good idea. It requires the right structure, the right advice, and the right moment to move.